Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.
Breast cancer is the second leading cause of cancer death among women, and its related treatment has been attracting significant attention over the past decades. Among the various treatments, targeted therapy has shown great promise as a precision treatment, by binding to cancer cell-specific biomarkers. So far, great achievements have been made in targeted therapy of breast cancer. In this review, we first discuss cell-specific biomarkers, which are not only useful for classification of breast cancer subtyping but also can be utilized as goals for targeted therapy. Then, the innovative and generic-targeted biopharmaceuticals for breast cancer, including monoclonal antibodies, non-antibody proteins and small molecule drugs, are reviewed. Finally, we provide our outlook on future developments of biopharmaceuticals, and provide solutions to problems in this field.
School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Mei
M
Liu
School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.|Department of Laboratory Medicine, Nanjing Drum Tower Hospital Clinical College, Nanjing University, Nanjing, China.
Zhiyang
Z
Li
School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China.
Jingjing
J
Yang
School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China.
Yanyun
Y
Jiang
School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Zhongsi
Z
Chen
School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China.
Zeeshan
Z
Ali
School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.
Nongyue
N
He
School of Chemistry and Chemical Engineering, Southeast University, Nanjing, China.
Zhifei
Z
Wang
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis; D001940:Breast / Q000187:drug effects* / Q000473:pathology; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor